Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 7/20 | 0.57 |
| ▸ | EPAS1 | Q99814 | 7/20 | 0.57 |
| ▸ | KIT | P10721 | 6/20 | 0.57 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 6/20 | 0.55 |
| ▸ | BCR | P11274 | 6/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | SYK | P43405 | 2/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
| ▸ | FYN | P06241 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 2/20 | 0.54 |
| ▸ | LYN | P07948 | 2/20 | 0.54 |
| ▸ | FGR | P09769 | 2/20 | 0.54 |
| ▸ | BRAF | P15056 | 2/20 | 0.54 |
| ▸ | NQO2 | P16083 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2448819 | 0.90 | ABL1 (0.61) | KITFLT3ABL1BCRPDGFRA | |
| SCHEMBL28684962 | 0.82 | SMN1; SMN2 (0.71) | HIF1AEPAS1KITFLT3ABL1 | |
| SCHEMBL15477705 | 0.79 | ABL1 (0.60) | HIF1AEPAS1KITFLT3ABL1 | |
| SCHEMBL4902292 | 0.77 | ABL1 (0.86) | KITFLT3ABL1BCRPDGFRA | |
| SCHEMBL14845834 | 0.77 | BTK (0.67) | HIF1AEPAS1BTKMAPK14LMNA | |
| SCHEMBL5951546 | 0.76 | ABL1 (0.75) | KITFLT3ABL1BCRPDGFRA | |
| SCHEMBL28300862 | 0.75 | BTK (0.68) | HIF1AEPAS1BTKLMNAMAPT | |
| SCHEMBL8191704 | 0.75 | ABL1 (0.72) | KITFLT3ABL1BCRPDGFRA | |
| SCHEMBL878663 | 0.75 | BTK (0.64) | HIF1AEPAS1BTKMAPK14LMNA | |
| SCHEMBL413398 | 0.74 | MAPK14 (0.53) | HIF1AEPAS1KITFLT3ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106026-A1 | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer | OHTSURU AKIRA | 2006-05-18 | — | — | US | disclosed |
| CN-1671389-A | 4- (4-methylpiperazin-1-ylmethyl) -N- [ 4-methyl-3-yl) pyrimidin-2-ylamino) phenyl ] -benzamide for the treatment of anaplastic thyroid cancer | NOVARTIS AG (CH) | 2005-09-21 | — | — | CN | disclosed |
| WO-2004009088-A1 | 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-N-[4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO)PHENYL]-BENZAMIDE FOR TREATING ANAPLASTIC THYROID CANCER | NOVARTIS AG (CH) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106026-A1 | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer | TPO, THRA, TSHR | HIF1A 3328/4885EPAS1 3720/4885KIT 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.